SUBSCRIBE
SUBSCRIBE
News   Drug Development

Capstone Therapeutics Announces Completion of Enrollment for AZX100 Phase 2 Clinical Trial in Dermal Scarring Following Shoulder Surgery

January 5, 2010 | 
1 min read
TEMPE, Ariz., Jan. 5, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the completion of enrollment for its AZX100 Phase 2 clinical trial in dermal scarring following shoulder surgery.
Clinical research Phase II
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ECLIPSEBIO
The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
July 10, 2025
 · 
1 min read
 · 
Lori Ellis
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business consultant. Hands help a businessman is falling from a graph vector
Rare diseases
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Dementia and mental health recovery treatment and Alzheimer brain memory disease therapy concept as old trees recovering as a neurology or psychology and psychiatry cure metaphor with 3D illustration elements on a white background.
Startups
Longevity Biotechs Strive for Better Aging—Not Just Life Extension
July 9, 2025
 · 
3 min read
 · 
Tristan Manalac